Anonymous ID: 99aef9 Aug. 2, 2020, 12:22 p.m. No.10162945   🗄️.is 🔗kun   >>3020 >>3044

>>10161947 Fake news NBC claim on HCQ, pb notable

 

I posted this before, but was ignored. That's fine. I don't really care anymore. Or, is it "I really don't care anymore." Whatever.

 

Patent Application Search Terms: “coronavirus AND quinine AND zinc AND virus AND malaria AND hydroxycholoqine”.

 

You can download the pdf at www.pat2pdf.org.

 

20040138187 Therapeutic treatment methods, filed in August of 2003, but it claims priority to a provisional application filed in August of 2002.

 

HOLLIS-EDEN PHARMACEUTICALS, INC.

 

Paragraph [0033]- F1C is the formula 1 compound. It is the general name they use for their formulation.

 

Paragraph [0016] to [0017]- They disclose that their formulation FC1 can include salts, such as zinc ions.

 

Paragraph [0378]- Mentions that liposomal formulations can be used to enhance delivery to certain types of cells. The liposomes can include a peptide from an infectious agent such as a malaria parasite, a virus or a tumor associated antigen.

 

Paragraph [0419]- The F1Cs can be considered for use in a broad scope of infections…since the compounds generally enhance Th1 immune responses and/or reduce Th2 immune responses and/or reduce inflammation or its symptoms. In treating chloroquine resistant or sensitive malaria, the F1Cs have essentially the same activity. Th1 and Th2 are helper T cells ([0004]).

 

Paragraph [0420] to [0421]- Exemplary viral infections that the F1Cs can be used to treat, prevent or ameliorate include infections by one or more DNA or RNA viruses, or a symptom(s) associated with such infection(s), such as a… Coronaviruses…

 

Paragraph [0438]- For subjects who have a viral or parasite infection and are in the course of a F1C treatment, other treatments can also be administered to the subject, e.g.,…quinine, berberine, and/or primaquine for subjects having or subject to developing a malaria infection.

 

There is a similar patent application that was filed in July of 2005.